ELUMASSIST Trademark

Trademark Overview

On Tuesday, June 26, 2018, a trademark application was filed for ELUMASSIST with the United States Patent and Trademark Office. The USPTO has given the ELUMASSIST trademark a serial number of 88015199. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, June 20, 2022. This trademark is owned by Alkermes Pharma Ireland Limited. The ELUMASSIST trademark is filed in the Medical & Beauty Services & Agricultural Services category with the following description:

Health care and medical information services in the field of support program for patients, patient families and caregivers in the administration of pharmaceutical preparations for the treatment of diseases mediated by an opioid receptor, namely, major depressive disorder, chronic depression, severe unipolar recurrent major depressive episodes, dysthymic disorder, depressive neurosis and neurotic depression, melancholic depression, atypical depression, reactive depression, treatment resistant depression, seasonal affective disorder and pediatric depression, premenstrual syndrome, premenstrual dysphoric disorder, hot flashes, bipolar disorders or manic depression, bipolar disorder and cyclothymic disorder, anxiety, post-traumatic stress disorder, obsessive compulsive disorder and borderline personality disorder
elumassist

General Information

Serial Number88015199
Word MarkELUMASSIST
Filing DateTuesday, June 26, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, June 20, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 19, 2019

Trademark Statements

Pseudo MarkELUM ASSIST
Goods and ServicesHealth care and medical information services in the field of support program for patients, patient families and caregivers in the administration of pharmaceutical preparations for the treatment of diseases mediated by an opioid receptor, namely, major depressive disorder, chronic depression, severe unipolar recurrent major depressive episodes, dysthymic disorder, depressive neurosis and neurotic depression, melancholic depression, atypical depression, reactive depression, treatment resistant depression, seasonal affective disorder and pediatric depression, premenstrual syndrome, premenstrual dysphoric disorder, hot flashes, bipolar disorders or manic depression, bipolar disorder and cyclothymic disorder, anxiety, post-traumatic stress disorder, obsessive compulsive disorder and borderline personality disorder

Classification Information

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, January 25, 2019
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAlkermes Pharma Ireland Limited
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressDublin
IE
Party NameAlkermes Pharma Ireland Limited
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressDublin
IE

Trademark Events

Event DateEvent Description
Tuesday, June 21, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, June 20, 2022ABANDONMENT - NO USE STATEMENT FILED
Wednesday, October 20, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 19, 2021SOU EXTENSION 5 GRANTED
Wednesday, October 13, 2021SOU EXTENSION 5 FILED
Tuesday, October 19, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, October 13, 2021SOU TEAS EXTENSION RECEIVED
Thursday, April 15, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, April 13, 2021SOU EXTENSION 4 GRANTED
Tuesday, April 13, 2021SOU EXTENSION 4 FILED
Tuesday, April 13, 2021SOU TEAS EXTENSION RECEIVED
Saturday, October 31, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 29, 2020SOU EXTENSION 3 GRANTED
Thursday, October 29, 2020SOU EXTENSION 3 FILED
Thursday, October 29, 2020SOU TEAS EXTENSION RECEIVED
Friday, April 24, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, April 22, 2020SOU EXTENSION 2 GRANTED
Wednesday, April 22, 2020SOU EXTENSION 2 FILED
Wednesday, April 22, 2020SOU TEAS EXTENSION RECEIVED
Saturday, October 19, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 17, 2019SOU EXTENSION 1 GRANTED
Thursday, October 17, 2019SOU EXTENSION 1 FILED
Thursday, October 17, 2019SOU TEAS EXTENSION RECEIVED
Tuesday, May 14, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 19, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 19, 2019PUBLISHED FOR OPPOSITION
Wednesday, February 27, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, February 11, 2019ASSIGNED TO LIE
Saturday, January 26, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, January 25, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, January 24, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, January 24, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, October 17, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, October 17, 2018NON-FINAL ACTION E-MAILED
Wednesday, October 17, 2018NON-FINAL ACTION WRITTEN
Tuesday, October 16, 2018ASSIGNED TO EXAMINER
Saturday, June 30, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, June 29, 2018NEW APPLICATION ENTERED

Related Keywords

elumassist disorder depression depressive premenstrual treatment bipolar major pediatric melancholic reactive